We are live on ! Find out more

Puma Biotechnology

PBYI

Market cap $493M

9.55 USD

+0.14

1.49%

At close Updated Sep 4, 4:00 PM EDT

Pre-market

After hours

9.55

0.00

0%

1 day

1.49%

5 days

5.88%

1 month

22.44%

3 months

36.23%

6 months

49.22%

Year to date

65.51%

1 year

86.89%

5 years

31%

10 years

-83.67%

About: Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also, it is developing Alisertib, a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis, resulting in apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.

Employees: 179

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 36.4%

Neutral 54.5%

Negative 9.1%

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology reported its inducement awards granted in August 2026, as required under Nasdaq Listing Rule 5635(c)(4).

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Zacks Investment Research

Is Puma Biotechnology (PBYI) a Great Value Stock Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Is Puma Biotechnology (PBYI) a Great Value Stock Right Now?

Zacks Investment Research

PBYI Q2 Earnings & Sales Beat Estimates, 2026 Guidance Raised

Puma Biotechnology tops Q2 earnings and revenue estimates, raises its 2026 guidance, and outlines upcoming alisertib study milestones as Nerlynx sales climb.

PBYI Q2 Earnings & Sales Beat Estimates, 2026 Guidance Raised

Puma Biotechnology, Inc. (PBYI) Q2 2026 Earnings Call Transcript

Puma Biotechnology, Inc. (PBYI) Q2 2026 Earnings Call Transcript

Puma Biotechnology, Inc. (PBYI) Q2 2026 Earnings Call Transcript

Puma Biotechnology Q2 Earnings Call Highlights

Puma Biotechnology NASDAQ: PBYI reported second-quarter 2026 total revenue of $56.5 million, including $53.6 million in net product revenue from NERLYNX and $2.9 million in royalty revenue. The company posted GAAP net income of $8.2 million, or $0.16 per diluted share, compared with a net loss of $3.8 million, or $0.07 per share, in the first quarter.

Puma Biotechnology Q2 Earnings Call Highlights

Zacks Investment Research

Puma Biotech (PBYI) Q2 Earnings and Revenues Top Estimates

Puma Biotech (PBYI) came out with quarterly earnings of $0.19 per share, beating the Zacks Consensus Estimate of $0.1 per share. This compares to earnings of $0.15 per share a year ago.

Puma Biotech (PBYI) Q2 Earnings and Revenues Top Estimates

Puma Biotechnology Reports Second Quarter 2026 Financial Results

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology will host a conference call beginning at 1:30 p.m. PT on Aug. 6, following release of its earnings results for 2Q-2026.

Puma Biotechnology Reports Second Quarter 2026 Financial Results

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology announced its inducement awards granted for July 2026, as required under Nasdaq Listing Rule 5635(c)(4).

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Zacks Investment Research

Earnings Preview: Puma Biotech (PBYI) Q2 Earnings Expected to Decline

Puma Biotech (PBYI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Puma Biotech (PBYI) Q2 Earnings Expected to Decline

Puma Biotechnology to Host Conference Call to Discuss Second Quarter 2026 Financial Results

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology will host a conference call at 1:30 p.m. PT on August 6, 2026, following release of its 2Q-2026 results.

Puma Biotechnology to Host Conference Call to Discuss Second Quarter 2026 Financial Results

See News Rankings

Price charts implemented using Lightweight Charts™